Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
353
resultados
Última actualización
25/07/2026 [07:57:00]
Resultados 100 a 125 de 353
Resumen de: WO2026141950A1
The present application provides: a spectroscopic analysis substrate for diagnosing dementia, comprising a hydrophilized graphene layer; and a spectroscopic device comprising same. More specifically, the present application provides: a spectroscopic analysis substrate for diagnosing dementia, having improved accuracy due to increased binding force and selectivity for amyloid beta, the substrate comprising a hydrophilized graphene layer; and a spectroscopic device comprising the spectroscopic analysis substrate.
Resumen de: US20260186004A1
0000 It has been established that increased levels of lactylated of tau protein in the brain and CNS is associated with tauopathies and neurodegenerative diseases, and increased levels of lactylated lysine on tau protein has been established as a marked for AD. Compositions and methods for the detection and treatments of tauopathies have been developed. In some forms, the methods identify and quantify lactylated lysine on tau protein in a biological sample from a subject to diagnose a tauopathy, such as AD. In some forms, the methods identify a subject as having or at risk of having a tauopathy. In some forms, the methods include treating the tauopathy. Compositions to identify a tauopathy include lactylated tau binders, such as antibodies are also described. Compositions to treat or prevent a tauopathy, such as lactylated tau peptides having a defined lactyllysine, are also described.
Resumen de: WO2026142185A1
In a surface-enhanced Raman scattering-based method for testing drug reactivity of cerebrovascular cells, a SERS substrate is manufactured. A SERS substrate array including a plurality of the SERS substrates is manufactured. Cells are cultured on the SERS substrate array. A drug is administered to the cultured cells. A Raman signal is measured from the cells to which the drug is administered. An optimal drug is selected from among the administered drugs on the basis of the measured Raman signal.
Resumen de: JP2026110170A
【課題】本発明者らは、特に老化組織において炎症を抑制し得る素材をスクリーニングする技術の提供を主な目的とした。【解決手段】上記課題は、工程Ｂ：１５回以上継代された血管内皮細胞に被験物質を接触させる工程、並びに工程Ｃ：ＩＬ－６、ＩＬ－８、ＣＸＣＬ１、ＰＡＩ－１、ＭＭＰ－１、ＩＣＡＭ－１、ＶＣＡＭ－１、Ｅ－ｓｅｌｅｃｔｉｎ、及びＣＣＬ２からなる群より選択される少なくとも１種の炎症関連因子の、工程Ｂで被験物質を接触させた血管内皮細胞における発現量を評価する工程を含む方法により、解決され得る。【選択図】なし
Resumen de: US20260183364A1
The present disclosure relates to methods for treating or alleviating a fetal alcohol spectrum disorder (FASD) in a subject, the method comprising administering to the subject an effective amount of an apolipoprotein E (APOE)-modulating therapeutic, thereby treating or alleviating the FASD.
Resumen de: US20260185138A1
0000 A coupled tethered enzyme luminescence assay for measuring the amount of enzymatic activity of neural specific enolase in a liquid blood sample taken from a patient. The assay has a test well and a positive control well. The test well has a number of components including an inhibitor and a number of first tethered enzyme nanobots formed by tethering pyruvate kinase enzyme to silica nanoparticles, and a number of second enzyme nanobots formed by tethering luciferase molecules to silica nanoparticles for oriented immobilization of the tethered enzymes pyruvate and luciferase. The pyruvate kinase and luciferase enzymes have two differing types of affinity tags. One type of affinity tag facilitates extraction of enzymes from a liquid and another affinity tag for tethering to a silica nanoparticle. The positive control well includes the components of the test well and an added preset amount of enolase enzyme.
Resumen de: WO2026142290A1
The present invention relates to a biomarker-specific binding probe and a use thereof. By introducing the probe into a nanopore, it is possible to accurately and rapidly detect the presence and abundance of a specific biomarker in a sample.
Resumen de: US20260185056A1
An in vitro method of producing a fused tissue culture with at least three different tissues including selecting a spatial shape for attaching the at least three different tissues to each other, placing the at least three different tissues into contact in the spatial shape, culturing the at least three different tissues under conditions that maintains tissue fusion of the at least three different tissues is disclosed. Further provided is a tissue culture comprising a planar or linear fusion of at least three different neural or neuronal tissues, uses thereof and means for its production.
Resumen de: JP2024019568A
To provide enrichment of an antigen-specific antibody for analytical and therapeutic use.SOLUTION: The present invention relates to a method for eliminating the interference described in the specification using particles (e.g., microparticles, nanoparticles; magnetic, non-magnetic) containing surfaces containing the capturing portions described in the specification, or enriching biomarkers, especially antibodies, prior to diagnostic testing, or isolating and using the antibodies for prophylactic or therapeutic purposes. The method described in the specification is a simple, efficient, and cost-effective method for the conditioning of biological samples for managing and mitigating a number of known sample-specific interferences that can lead to erroneous test results and increased risk to patient safety, such as heterophil antibodies in patients treated with monoclonal mouse antibodies or those receiving them for diagnostic purposes.SELECTED DRAWING: None
Resumen de: US20260184764A1
0000 The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.
Resumen de: US20260184772A1
The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.
Resumen de: WO2026137685A1
The present application relates to the technical field of immunochromatography, and in particular, to a test strip for detecting β-amyloid protein and the use thereof. In the present application, colored microspheres are conjugated to a β-amyloid monoclonal antibody via covalent bonds, and then the conjugate is coated onto a conjugate pad. Compared with colloidal gold, the colored microspheres exhibit greater stability and higher sensitivity. Additionally, the colored microspheres feature bright and diverse colors, uniform particle sizes, good monodispersity, and strong reproducibility of detection results. The test strip provided by the present application has the advantages of simplicity, rapidity and high timeliness, requires no additional reagents, instruments and professional personnel, and supports on-site operation. By means of simply applying a to-be-detected sample to a sample loading port of the test strip, a detection result can be interpreted within 15 min. The result interpretation is visual, intuitive, accurate and straightforward, with a low risk of human errors such as false positives and false negatives.
Resumen de: AU2024388318A1
The present disclosure provides precision medicine or personalized therapy of using a Sigma-1 receptor agonist in treating neurological disease or disorder. The precision medicine or personalized therapy involves patient selection through differentially expressed genes or affected biological pathways related to the Sigma-1 receptor agonist therapy. Also provided are kits for practicing the methods.
Resumen de: US20260185993A1
0000 A functional peptide modified magnetic composite nanobead, and a method and an application thereof for detecting β-secretase (BACE1) and screening its inhibitors are provided. The chemical composition of the magnetic composite nanobead is: ferroferric oxide (Fe<3>O<4>) nanoclusters used as magnetic cores, the surface of the magnetic cores coated with a silica shell, the surface of the shell connected with an ethylene diamine tetraacetic acid (EDTA) modification layer, and Co<2+> or Ni<2+> ions chelated on the EDTA layer, and the Cy5 fluorescein labeled functional peptide coated on the surface of magnetic composite nanobead by the interaction between Co<2+> or Ni<2+> ions and hexahistidine-tag.
Resumen de: US20260184770A1
Disclosed herein are methods of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain using a tau PET level.
Resumen de: KR20260100566A
본 발명은 알파-시누클레인 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 서열번호 1 내지 12의 염기서열로 이루어진 군 중에서 선택되는 알파-시누클레인(α-synuclein) 단백질에 특이적으로 결합하는 DNA 앱타머(aptamer), 상기 앱타머를 유효성분으로 포함하는 알파-시누클레인 단백질 검출용 조성물, 검출용 키트, 검출용 칩 또는 마이크로어레이에 관한 것이며, 또한 본 발명은 본 발명의 DNA 앱타머를 이용한 알파-시누클레인 단백질의 검출방법, 퇴행성 뇌질환의 진단을 위한 정보 제공 방법, 퇴행성 뇌질환의 진단용 조성물 및 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물에 관한 것이다.
Resumen de: CN121263693A
Provided herein are methods for detecting proteins and/or protein variants thereof, the methods comprising adding to a biological sample one or more small molecules and one or more protein binding agents wherein a protein crown is formed on a surface of the protein binding agent, and detecting the protein and/or protein variants thereof in the protein crown by antibody-based technology or proteomic technology. Also provided herein are methods for detecting one or more biomarkers or patterns of one or more biomarkers associated with a disease or health profile condition, as well as methods of diagnosing or predicting a disease in a subject. Compositions comprising one or more small molecules, one or more protein binding agents, and one or more biological samples are also provided.
Resumen de: WO2025146757A1
This method for quantifying plasmalogens comprises: a measurement sample preparation step for mixing a Schiff reagent with a specimen containing protein and plasmalogens to obtain a measurement sample; a control sample preparation step for mixing the specimen with a solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the extent of a first optical property of the measurement sample, the first optical property being obtained by reacting the Schiff reagent with an aldehyde generated from vinyl ether bonds of the plasmalogens, and measuring the extent of the optical property of the control sample; and a determination step for determining the concentration of plasmalogens in the specimen by comparing the correction extent, that is the extent to which the extent of the first optical property has been corrected by the extent of the optical property of the control sample, with the extent of a second optical property of a standard sample containing the Schiff reagent and a known concentration of plasmalogens, the second optical property being the optical property after the Schiff reagent has been reacted with the aldehyde generated from the vinyl ether bonds of the plasmalogens.
Resumen de: KR20260101594A
본원은 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다. 더욱 상세하게, 본원은 아밀로이드 베타와의 결합력 및 선택성 증가로 정확도가 개선된 친수화된 그래핀층을 포함하는 치매 진단용 분광분석용 기판 및 이를 포함하는 분광 장치를 제공한다.
Resumen de: CN122307115A
本发明提供一种生物标志物在制备轻度认知障碍风险评估产品中的用途，所述生物标志物包括Aβ寡聚体。单独的Aβ寡聚体标志物对MCI具有显著的预测价值，在区分认知正常与MCI的受试者时，其测试集受试者工作特征曲线下面积（AUC）即可达到 0.851（95% 置信区间:0.803 ‑ 0.895），证明其在区分出MCI受试者具有优越的性能。
Resumen de: CN122297687A
0001 本发明提供了乳酰化修饰PRDX5蛋白及其产品和应用，属于生物医药技术领域。本发明揭示了PRDX5 K71位点乳酰化修饰在COPD病理进程中的关键作用，其在COPD小鼠海马组织神经元乳酰化水平异常升高，且与小鼠认知功能障碍的发生发展密切相关；同时提供了靶向该位点的特异性干预方案，通过立体定位注射重组腺相关病毒PRDX5 K71R突变体降低或阻断K71位点发生乳酰化修饰的可能性，可有效改善COPD小鼠的学习记忆与空间定位能力，为认知功能障碍的机制研究与靶向防治提供了新的分子靶点和实验依据。
Resumen de: CN122307112A
0001 本申请涉及一种神经退行性变标志物检测试剂及检测方法。该神经退行性变标志物检测试剂包括产氧剂、催化剂和能够与待测样本中的待测神经退行性变标志物特异性结合的免疫检测试剂；其中，产氧剂在催化剂的作用下发生反应生成氧气，生成的氧气用于增加反应体系中的氧含量；免疫检测试剂能够利用反应液中的活性氧产生光信号，待测靶分子选自神经退行性变标志物。本申请提供的方案，能够在神经退行性变标志物浓度水平较低时，提高光信号值，有利于提高对神经退行性变标志物的检出能力。
Resumen de: CN122302156A
0001 本发明提供一种胆碱仿生双亲聚合物纳米盘，所述胆碱仿生双亲聚合物纳米盘的制备原料包括聚甲基丙烯酸酯共聚物；所述聚甲基丙烯酸酯共聚物由2‑甲基丙烯酰氧乙基磷酰胆碱与甲基丙烯酸己酯经聚合反应制备得到。该胆碱仿生双亲聚合物纳米盘具备高效穿越BBB的能力和脑靶向能力，在体外BBB模型和小鼠体内都能高效的通过胆碱转运受体跨越BBB，该胆碱仿生双亲聚合物纳米盘的盘状形态和纳米级尺寸促进了血管、基质和细胞屏障的有效渗透，具有卓越的实体瘤浸润能力。本发明提供一种上述的胆碱仿生双亲聚合物纳米盘的制备方法以及上述的胆碱仿生双亲聚合物纳米盘在制备脑肿瘤的检测试剂或脑肿瘤的预防、治疗药物中的应用。
Resumen de: WO2026145099A1
Provided in the present invention is the use of NUCB1 in the prevention and/or treatment of autoimmune diseases. Specifically provided in the present invention is the use of an NUCB1 gene, or a protein thereof, or a promoter thereof in the preparation of a composition or preparation, wherein the composition or preparation is used for preventing and/or treating autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof of the present invention can significantly prevent and/or treat autoimmune diseases, and is particularly effective against systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis, or Crohn's disease.
Nº publicación: CN122297477A 30/06/2026
Solicitante:
山东大学
Resumen de: CN122297477A
0001 本发明涉及生物医药领域，公开了一种含有2,4‑噻唑环的化合物在抗衰老中的应用。含有2,4‑噻唑环的化合物为式X所示化合物或其药学上可接受的盐，其中式X化合物包括具有吡唑并嘧啶骨架的式I类化合物和具有吲哚骨架的式II类化合物。本发明人首次发现IL4I1是调控细胞衰老的关键分子，并阐明了式X化合物通过靶向IL4I1，解除IL4I1对EIF4B的泛素化降解，上调EIF4B‑PGAM5轴表达，从而维持线粒体稳态、延缓细胞及组织衰老的作用机制。实验结果表明，本发明所述含有2,4‑噻唑环的化合物可有效预防放化疗诱导的细胞衰老，减轻放疗诱导的小鼠整体衰老，改善运动功能，降低衰老相关分泌表型因子分泌，缓解器官纤维化。本发明为开发新型抗衰老药物提供了新的化学分子基础和作用靶点。
BOPI
Sede Electrónica
